BioSpace News Archive

Despite yesterday’s announcement by 9 Meters Biopharma that larazotide acetate drug trials had been discontinued, Beyond Celiac remains resolute in driving research to find treatment and a cure for celiac disease by 2030.

The U.S. Medical Device Manufacturers market size was valued at US$ 177.0 billion in 2021 and is expected to hit US$ 265.1 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.85% from 2022 to 2030.

Scientists at St. Jude Children’s Research Hospital identified a molecular mechanism that in a preclinical study unlocked the promise of CAR T–cell therapy for treatment of solid tumors.

Data Bridge Market Research latest research report, titled “Biopharmaceuticals Market ” offers a detailed analysis of the market drivers, size, share, demand, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

Despite overall improvements to care for a heart attack, women are less likely to receive timely treatment, according to a new study in Annals of Emergency Medicine.

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that Peter Rands, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in a fireside chat at the H. C. Wainwright 1st Annual Mental Health Conference.

3Spine, Inc., a medical device company developing total joint replacement for the lumbar spine, announced FDA Investigational Device Exemption approval for their US pivotal clinical trial.

In keeping with the Center for Disease Control’s final sign-off to Pfizer-BioNTech’s and Moderna’s kid-size coronavirus disease 2019 (COVID-19) vaccine, New York children ages six months to five years – which constitute 20 million youngsters nationwide – are now one step closer to battling the virus.

The American Diabetes Association® (ADA), the leading global diabetes research, advocacy, and education organization, applauds U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME) for introducing legislation today during a joint press conference on Capitol Hill in Washington, D.C., which aims to make insulin more affordable for millions of Americans with diabetes who rely on the drug to live.

Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that the first patient was treated in a feasibility study evaluating the Alpha DaRT as a neoadjuvant therapy in patients with prostate cancer at the Rambam Health Care Center in Haifa, Israel.